A Unique Mammalian Suspension Technology Enhances Scalable rAAV Production with Pro10 Cell Line

Revolutionizing Gene Therapy: Viralgen’s Pro10™ Cell Line for Scalable and Robust rAAV Production

The Pro10™ cell line is a new technology aimed at improving the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology allows for scalable and robust production of rAAVs, addressing the challenges of large-scale manufacturing in AAV gene therapies.

Viralgen utilizes the Pro10™ cells as the foundation for a robust and scalable rAAV vector manufacturing process. These cells have been optimized for rAAV production and successfully scaled up to 2000L, demonstrating consistent and reproducible cell growth rates. They exhibit similar productivity in small and large-scale bioreactors and can produce different AAV serotypes. The Pro10™ cells play a crucial role in Viralgen’s platform process for manufacturing AAV vectors and have been vital in producing groundbreaking gene therapies.

The HEK293 derived animal component-free suspension Pro10™ cell line is described in full in the PDF, which highlights its ability to reduce process development time and costs. This innovative technology is a promising advancement in the field of gene therapy manufacturing, offering a solution to the challenges faced in large-scale production of AAV vectors.

Leave a Reply

Roger Goodell contemplates adding Von Miller to Commissioner Exempt list Previous post NFL Commissioner Goodell Pauses on Placing Von Miller on Commissioner Exempt List Amid Assault Allegations
Trump’s Partnership with Truth Social Boosts Him Into the Ranks of the World’s 500 Wealthiest Individuals Next post Former President Donald Trump Adds $4 Billion to His Net Worth: What You Need to Know